Progress in the development of immune-based therapies for type 1 diabetes mellitus

BioDrugs

Volumn 20, Issue 6, 2006, Pages 341-350

  Von Herrath, Matthias ^a   Rottembourg, Diane ^a   Bresson, Damien ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; AUTOANTIGEN; CD3 ANTIBODY; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIAPEP277; DNA VACCINE; FAS LIGAND; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; HEAT SHOCK PROTEIN 60; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HUMAN INSULIN; IMMUNOMODULATING AGENT; INSULIN; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY CD3; NICOTINAMIDE; OKT 3; OKT 4; PEPTIDE P277; PERFORIN; PLACEBO; POLYCLONAL ANTISERUM; PROINSULIN; TETRAMER; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANEMIA; ANTIGEN PRESENTING CELL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; ENVIRONMENTAL FACTOR; FEVER; GENETIC SUSCEPTIBILITY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NOSE IRRITATION; PANCREAS ISLET BETA CELL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE ACTIVATION; TRANSGENE; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

EID: 33846170111     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200620060-00004     Document Type: Review

References (72)

1. Maier LM, Wicker LS. Genetic susceptibility to type 1 diabetes. Curr Opin Immunol 2005; 17 (6): 601-8
2. Jones EY, Fugger L, Strominger JL, et al. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 2006; 6 (4): 271-82
3. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36 (4): 337-8
4. Vella A, Cooper JD, Lowe CE, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005; 76 (5): 773-9
5. Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006; 38 (6): 617-9
6. Lammi N, Karvonen M, Tuomilehto J. Do microbes have a causal role in type 1 diabetes? Med Sci Monit 2005; 11 (3): RA63-9
7. Daneman D. Type 1 diabetes. Lancet 2006; 367 (9513): 847-58
8. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev 2005; 204: 232-49
9. Kent SC, Chen Y, Bregoli L, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005; 435 (7039): 224-8
10. Nakayama M, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435 (7039): 220-3
11. Aly T, Devendra D, Eisenbarth GS. Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes. Am J Ther 2005; 12 (6): 481-90
12. Wong FS, Wen L, Tang M, et al. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 2004; 53 (10): 2581-7
13. Tian J, Zekzer D, Lu Y, et al. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J Immunol 2006; 176 (4): 2654-61
14. Martin S, Pawlowski B, Greulich B, et al. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 1992; 15 (1): 66-74
15. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352 (25): 2598-608
16. Pozzilli P. The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention. Diabetes Metab Res Rev 2002; 18 (4): 257-9
17. Gale EA, Bingley PJ, Emmett CL, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363 (9413): 925-31
18. Alleva DG, Gaur A, Jin L, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002; 51 (7): 2126-34
19. Martin S, Schernthaner G, Nerup J, et al. Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 1991; 34 (6): 429-34
20. Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII): IMDIAB Group. Diabetologia 2000; 43 (8): 1000-4
21. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19 (4): 238-46
22. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358 (9295): 1749-53
23. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54 (6): 1763-9
24. Chase HP, Butler-Simon N, Garg SK, et al. Cyclosporine A for the treatment of new-onset insulin-dependent diabetes mellitus. Pediatrics 1990; 85 (3): 241-5
25. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet 1986; 2 (8499): 119-24
26. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 1998; 47 (6): 980-4
27. Kupila A, Sipila J, Keskinen P, et al. Intranasally administered insulin intended for prevention of type 1 diabetes: a safety study in healthy adults. Diabetes Metab Res Rev 2003; 19 (5): 415-20
28. Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27 (10): 2348-55
29. Diamyd Medical [online]. Available from URL: http://www.diamyd.com [Accessed 2006 Nov 1]
30. von Herrath MG. Vaccination to prevent type 1 diabetes. Expert Rev Vaccines 2002; 1 (1): 25-8
31. McDevitt H. Specific antigen vaccination to treat autoimmune disease. Proc Natl Acad Sci U S A 2004; 101 Suppl. 2: 14627-30
32. Homann D, Dyrberg T, Petersen J, et al. Insulin in oral immune 'tolerance': a one-amino acid change in the B chain makes the difference. J Immunol 1999; 163 (4): 1833-8
33. Tang Q, Adams JY, Tooley AJ, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7 (1): 83-92
34. Bresson D, Togher L, Rodrigo E, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116 (5): 1371-81
35. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6 (10): 1167-75
36. Makhlouf L, Grey ST, Dong V, et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation 2004; 77 (7): 990-7
37. Maki T, Ichikawa T, Blanco R, et al. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci U S A 1992; 89 (8): 3434-8
38. Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994; 91 (1): 123-7
39. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32 (6): 535-9
40. Prentice HG, Blacklock HA, Janossy G, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982; 1 (8274): 700-3
41. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999; 68 (11): 1632-7
42. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68 (5): 608-16
43. von Herrath MG, Coon B, Wolfe T, et al. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol 2002; 168 (2): 933-41
44. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002 May 30; 346 (22): 1692-8
45. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9 (9): 1202-8
46. Bisikirska B, Colgan J, Luban J, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005; 115 (10): 2904-13
47. Herold KC, Burton JB, Francois F, et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest 2003; 111 (3): 409-18
48. Elias D, Markovits D, Reshef T, et al. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A 1990; 87 (4): 1576-80
49. Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994; 343 (8899): 704-6
50. Elias D, Reshef T, Birk OS, et al. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A 1991; 88 (8): 3088-91
51. Bowman M, Atkinson MA. Heat shock protein therapy fails to prevent diabetes in NOD mice. Diabetologia 2002; 45 (9): 1350-1
52. Giannoukakis N. DiaPep277 (DeveloGen). Curr Opin Investig Drugs 2005; 6 (10): 1043-50
53. Zanin-Zhorov A, Nussbaum G, Franitza S, et al. T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. Faseb J 2003; 17 (11): 1567-9
54. Zanin-Zhorov A, Cahalon L, Tal G, et al. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006; 116 (7): 2022-32
55. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4 (3): 390-401
56. Frentsch M, Arbach O, Kirchhoff D, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 2005; 11 (10): 1118-24
57. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005; 11 (10): 1113-7
58. Endl J, Rosinger S, Schwarz B, et al. Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes 2006; 55 (1): 50-60
59. Pinkse GG, Tysma OH, Bergen CA, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A 2005; 102 (51): 18425-30
60. Toma A, Haddouk S, Briand JP, et al. Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients. Proc Natl Acad Sci U S A 2005; 102 (30): 10581-6
61. Reijonen H, Novak EJ, Kochik S, et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002; 51 (5): 1375-82
62. Reijonen H, Mallone R, Heninger AK, et al. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes 2004; 53 (8): 1987-94
63. Mallone R, Nepom GT. Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes. Am J Ther 2005; 12 (6): 534-50
64. Nepom GT. Tetramer analysis of human autoreactive CD4-positive T cells. Adv Immunol 2005; 88: 51-71
65. Casares S, Hurtado A, McEvoy RC, et al. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 2002; 3 (4): 383-91
66. Yang J, Danke NA, Berger D, et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol 2006; 176 (5): 2781-9
67. Oling V, Marttila J, Ilonen J, et al. GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun 2005; 25 (3): 235-43
68. Souza F, Simpson N, Raffo A, et al. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 2006 Jun; 116 (6): 1506-13
69. Turvey SE, Swart E, Denis MC, et al. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest 2005; 115 (9): 2454-61
70. Nishio J, Gaglia JL, Turvey SE, et al. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 2006; 311 (5768): 1775-8
71. Trucco M. Regeneration of the pancreatic beta cell. J Clin Invest 2005; 115 (1): 5-12
72. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987; 65 (1): 30-6